Relay Therapeutics (RLAY)
Relay Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
44.0M
Short interest
settlement 2026-10-15
16.0
Days to cover
+3.4 days vs prior
79.3%
Short share of volume
2026-11-02
440,875
Fails to deliver
settlement 2026-10-13
Thu 5 Nov
Next earnings
estimated date
-$120.5M
Insider flow, 90 days
0 buys, 13 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RLAY is 44,026,826 shares, down 460,602 shares over the last month. Over the last 48 readings it ranged from 11,611,974 shares (15 November 2024) to 46,746,942 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 2.8M shares a day that is 16.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rlay" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 44,026,826 | -5.8% | 2,752,033 | 16.00 |
| 2026-09-30 | 46,746,942 | +5.1% | 3,712,736 | 12.59 |
| 2026-09-15 | 44,487,428 | +2.1% | 3,128,440 | 14.22 |
| 2026-08-31 | 43,550,416 | +5.3% | 2,602,528 | 16.73 |
| 2026-08-14 | 41,359,202 | +2.8% | 1,915,396 | 21.59 |
| 2026-07-31 | 40,250,044 | -5.4% | 2,311,874 | 17.41 |
| 2026-07-15 | 42,557,689 | -1.1% | 3,179,992 | 13.38 |
| 2026-06-30 | 43,041,464 | +12.9% | 5,945,327 | 7.24 |
| 2026-06-15 | 38,123,615 | +10.9% | 3,870,929 | 9.85 |
| 2026-05-29 | 34,389,240 | +19.3% | 5,989,092 | 5.74 |
| 2026-05-15 | 28,824,051 | +5.2% | 2,800,827 | 10.29 |
| 2026-04-30 | 27,410,626 | +1.5% | 3,142,590 | 8.72 |
| 2026-04-15 | 26,998,295 | +23.1% | 4,387,680 | 6.15 |
| 2026-03-31 | 21,938,652 | +10.6% | 2,139,517 | 10.25 |
| 2026-03-13 | 19,845,792 | +2.1% | 3,084,821 | 6.43 |
| 2026-02-27 | 19,437,056 | -2.3% | 1,986,807 | 9.78 |
| 2026-02-13 | 19,890,452 | -17.2% | 2,710,038 | 7.34 |
| 2026-01-30 | 24,025,317 | +7.3% | 2,524,730 | 9.52 |
| 2026-01-15 | 22,381,326 | +0.7% | 1,854,748 | 12.07 |
| 2025-12-31 | 22,232,137 | +9.5% | 2,332,582 | 9.53 |
| 2025-12-15 | 20,296,216 | -12.4% | 1,992,313 | 10.19 |
| 2025-11-28 | 23,160,072 | +8.4% | 2,119,627 | 10.93 |
| 2025-11-14 | 21,371,170 | +19.6% | 2,572,113 | 8.31 |
| 2025-10-31 | 17,870,256 | -18.5% | 2,123,201 | 8.42 |
| 2025-10-15 | 21,928,192 | -3.2% | 1,570,987 | 13.96 |
| 2025-09-30 | 22,643,430 | +0.6% | 1,800,001 | 12.58 |
| 2025-09-15 | 22,504,700 | -1.0% | 1,499,654 | 15.01 |
| 2025-08-29 | 22,729,030 | -0.1% | 932,719 | 24.37 |
| 2025-08-15 | 22,740,377 | +1.6% | 2,031,170 | 11.20 |
| 2025-07-31 | 22,378,280 | +4.0% | 3,578,835 | 6.25 |
| 2025-07-15 | 21,520,228 | +0.0% | 1,278,297 | 16.84 |
| 2025-06-30 | 21,520,044 | -4.5% | 1,824,773 | 11.79 |
| 2025-06-13 | 22,524,543 | -0.6% | 1,423,396 | 15.82 |
| 2025-05-30 | 22,648,303 | -2.2% | 1,394,514 | 16.24 |
| 2025-05-15 | 23,159,142 | +18.9% | 2,846,511 | 8.14 |
| 2025-04-30 | 19,472,502 | +6.0% | 2,088,710 | 9.32 |
| 2025-04-15 | 18,364,112 | +1.7% | 3,350,441 | 5.48 |
| 2025-03-31 | 18,058,839 | -5.6% | 2,679,703 | 6.74 |
| 2025-03-14 | 19,121,771 | +18.1% | 2,536,208 | 7.54 |
| 2025-02-28 | 16,188,685 | +2.5% | 1,823,326 | 8.88 |
| 2025-02-14 | 15,789,969 | +0.8% | 1,206,055 | 13.09 |
| 2025-01-31 | 15,660,482 | +3.0% | 2,415,593 | 6.48 |
| 2025-01-15 | 15,208,884 | +1.7% | 3,265,789 | 4.66 |
| 2024-12-31 | 14,952,673 | +23.8% | 2,066,696 | 7.24 |
| 2024-12-13 | 12,081,421 | +1.3% | 3,217,453 | 3.75 |
| 2024-11-29 | 11,930,533 | +2.7% | 1,898,486 | 6.28 |
| 2024-11-15 | 11,611,974 | -3.6% | 1,371,536 | 8.47 |
| 2024-10-31 | 12,043,516 | +1.6% | 1,144,285 | 10.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of RLAY volume is 79.3%, up 12.1 points over the last five sessions. Over the last 30 readings it ranged from 32.6% (23 October 2026) to 86.6% (30 October 2026). The latest reading is 16.5 points above the 30-session average of 62.8%, on 1.6M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 1.3M | 1.6M | 79.3% | 130 |
| 2026-10-30 | 1.5M | 1.7M | 86.6% | 838 |
| 2026-10-29 | 659K | 928K | 71.0% | 250 |
| 2026-10-28 | 547K | 1.1M | 49.9% | 44 |
| 2026-10-27 | 652K | 1.2M | 55.6% | 0 |
| 2026-10-26 | 281K | 418K | 67.2% | 60 |
| 2026-10-23 | 246K | 753K | 32.6% | 310 |
| 2026-10-22 | 282K | 742K | 38.0% | 0 |
| 2026-10-21 | 226K | 563K | 40.2% | 583 |
| 2026-10-20 | 239K | 591K | 40.4% | 2,316 |
| 2026-10-19 | 322K | 479K | 67.3% | 381 |
| 2026-10-16 | 565K | 892K | 63.4% | 65 |
| 2026-10-15 | 317K | 650K | 48.7% | 50 |
| 2026-10-14 | 440K | 1.0M | 43.6% | 1,097 |
| 2026-10-13 | 423K | 553K | 76.5% | 1 |
| 2026-10-12 | 361K | 964K | 37.5% | 493 |
| 2026-10-09 | 300K | 532K | 56.3% | 2,193 |
| 2026-10-08 | 720K | 960K | 75.0% | 2 |
| 2026-10-07 | 773K | 942K | 82.1% | 0 |
| 2026-10-06 | 967K | 1.3M | 72.8% | 55 |
| 2026-10-05 | 531K | 1.0M | 50.7% | 224 |
| 2026-10-02 | 769K | 1.0M | 75.1% | 1,100 |
| 2026-10-01 | 789K | 979K | 80.6% | 0 |
| 2026-09-30 | 539K | 758K | 71.1% | 50 |
| 2026-09-29 | 725K | 1.1M | 65.1% | 956 |
| 2026-09-28 | 289K | 437K | 66.2% | 802 |
| 2026-09-25 | 817K | 1.1M | 76.0% | 84 |
| 2026-09-24 | 1.0M | 1.5M | 68.0% | 2,198 |
| 2026-09-23 | 1.4M | 2.2M | 64.2% | 9,304 |
| 2026-09-22 | 1.5M | 1.8M | 83.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in RLAY is 440,875 shares, up 420,351 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (23 September 2026) to 440,875 shares (13 October 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 440,875 | $17.98 | $7.9M |
| 2026-10-09 | 20,524 | $17.41 | $357K |
| 2026-10-07 | 26,636 | $18.74 | $499K |
| 2026-10-06 | 12,859 | $19.39 | $249K |
| 2026-10-05 | 321,236 | $18.96 | $6.1M |
| 2026-09-25 | 253 | $17.73 | $4K |
| 2026-09-24 | 984 | $18.03 | $18K |
| 2026-09-23 | 4 | $19.35 | $77 |
| 2026-09-22 | 149 | $18.19 | $3K |
| 2026-09-21 | 44,266 | $18.84 | $834K |
| 2026-09-09 | 72,046 | $19.11 | $1.4M |
| 2026-09-08 | 50 | $19.04 | $952 |
| 2026-09-04 | 18,880 | $19.01 | $359K |
| 2026-08-31 | 883 | $18.77 | $17K |
| 2026-08-27 | 18 | $19.46 | $350 |
| 2026-08-26 | 49,014 | $20.57 | $1.0M |
| 2026-08-25 | 19 | $19.76 | $375 |
| 2026-08-24 | 7,981 | $19.44 | $155K |
| 2026-08-21 | 30,280 | $19.70 | $597K |
| 2026-08-14 | 42,458 | $19.93 | $846K |
| 2026-08-12 | 4,154 | $19.99 | $83K |
| 2026-08-04 | 25 | $18.78 | $470 |
| 2026-07-23 | 82 | $19.27 | $2K |
| 2026-07-21 | 52,362 | $19.18 | $1.0M |
| 2026-07-20 | 740 | $19.91 | $15K |
| 2026-07-17 | 1,061 | $19.37 | $21K |
| 2026-07-16 | 128 | $19.51 | $2K |
| 2026-07-14 | 182 | $18.73 | $3K |
| 2026-07-08 | 4,533 | $19.74 | $89K |
| 2026-07-06 | 9 | $18.65 | $168 |
Insider trades
SEC Form 4, newest first. JSONInsiders at RLAY reported 13 open-market sells worth $120.5M in the last 90 days and no open-market buys. Latest filing: Catinazzo Thomas (Chief Financial Officer) on 2026-10-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 1K | $18.62 | $27K | 104K |
| 2026-10-28 | Bergstrom Donald A | President, R&D | Sell | 2K | $18.62 | $42K | 397K |
| 2026-10-28 | Rahmer Peter | See remarks | Sell | 753 | $18.62 | $14K | 223K |
| 2026-10-07 | Patel Sanjiv | President and CEO | Sell | 48K | $18.10 | $872K | 471K |
| 2026-10-06 | Catinazzo Thomas | Chief Financial Officer | Sell | 206 | $19.26 | $4K | 105K |
| 2026-10-06 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $18.58 | $325K | 105K |
| 2026-09-08 | Patel Sanjiv | President and CEO | Sell | 48K | $18.94 | $913K | 520K |
| 2026-09-08 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $18.94 | $336K | 123K |
| 2026-09-08 | Bergstrom Donald A | President, R&D | Sell | 9K | $18.97 | $162K | 399K |
| 2026-08-26 | Rahmer Peter | See remarks | Sell | 5K | $20.03 | $90K | 224K |
| 2026-08-25 | SVF Pauling (Cayman) Ltd | 10% owner | Sell | 6.0M | $19.40 | $116.4M | 21.9M |
| 2026-08-17 | Patel Sanjiv | President and CEO | Sell | 48K | $20.33 | $980K | 568K |
| 2026-08-14 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $19.74 | $350K | 141K |
| 2026-07-28 | Rahmer Peter | See remarks | Sell | 748 | $18.61 | $14K | 228K |
| 2026-07-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 1K | $18.61 | $27K | 158K |
| 2026-07-28 | Bergstrom Donald A | President, R&D | Sell | 2K | $18.61 | $42K | 408K |
| 2026-07-07 | Patel Sanjiv | President and CEO | Sell | 48K | $19.58 | $944K | 616K |
| 2026-07-06 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $18.69 | $331K | 160K |
| 2026-07-06 | Bergstrom Donald A | President, R&D | Sell | 9K | $18.71 | $162K | 410K |
| 2026-06-30 | Rahmer Peter | See remarks | Grant | 3K | $6.95 | $21K | 229K |
| 2026-06-30 | Rahmer Peter | See remarks | Sell | 50K | $19.09 | $955K | 226K |
| 2026-06-30 | Patel Sanjiv | President and CEO | Grant | 3K | $6.95 | $21K | 664K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $17.01 | $301K | 177K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Exercise or conversion | 56K | $5.04 | $284K | 234K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Sell | 52K | $16.97 | $875K | 177K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Exercise or conversion | 52K | $4.45 | $229K | 229K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Sell | 62K | $16.97 | $1.0M | 177K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Exercise or conversion | 62K | $5.22 | $321K | 239K |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Sell | 56K | $16.97 | $956K | 177K |
| 2026-06-22 | Bergstrom Donald A | President, R&D | Sell | 93K | $16.94 | $1.6M | 419K |
| 2026-06-22 | Bergstrom Donald A | President, R&D | Exercise or conversion | 93K | $4.12 | $385K | 512K |
| 2026-05-14 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $12.86 | $228K | 195K |
| 2026-04-28 | Rahmer Peter | See remarks | Sell | 753 | $14.79 | $11K | 276K |
| 2026-04-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 972 | $14.79 | $14K | 213K |
| 2026-04-28 | Bergstrom Donald A | President, R&D | Sell | 1K | $14.79 | $22K | 419K |
| 2026-04-09 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $15.00 | $27K | 214K |
| 2026-04-09 | Catinazzo Thomas | Chief Financial Officer | Exercise or conversion | 2K | $5.22 | $9K | 216K |
| 2026-04-07 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $13.01 | $230K | 214K |
| 2026-03-09 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $10.06 | $178K | 232K |
| 2026-01-28 | Rahmer Peter | See remarks | Sell | 1K | $8.45 | $11K | 277K |
| 2026-01-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $8.45 | $14K | 249K |
| 2026-01-28 | Bergstrom Donald A | President, R&D | Sell | 3K | $8.45 | $23K | 420K |
| 2026-01-27 | Rahmer Peter | See remarks | Sell | 12K | $7.62 | $89K | 278K |
| 2026-01-27 | Catinazzo Thomas | Chief Financial Officer | Sell | 14K | $7.62 | $105K | 251K |
| 2026-01-27 | Bergstrom Donald A | President, R&D | Sell | 19K | $7.62 | $144K | 423K |
| 2026-01-06 | Patel Sanjiv | President and CEO | Sell | 43K | $7.82 | $338K | 661K |
| 2025-12-31 | Patel Sanjiv | President and CEO | Grant | 994 | $2.99 | $3K | 704K |
| 2025-12-31 | Rahmer Peter | See remarks | Grant | 994 | $2.99 | $3K | 338K |
| 2025-11-03 | Patel Sanjiv | President and CEO | Sell | 62K | $7.00 | $435K | 703K |
| 2025-10-29 | Rahmer Peter | See remarks | Sell | 21K | $7.50 | $160K | 337K |
| 2025-10-28 | Rahmer Peter | See remarks | Sell | 19K | $7.29 | $139K | 359K |
| 2025-10-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 22K | $7.29 | $158K | 314K |
| 2025-10-28 | Bergstrom Donald A | President, R&D | Sell | 31K | $7.29 | $225K | 522K |
| 2025-07-29 | Rahmer Peter | See remarks | Sell | 16K | $3.68 | $58K | 378K |
| 2025-07-29 | Catinazzo Thomas | Chief Financial Officer | Sell | 18K | $3.68 | $68K | 335K |
| 2025-07-29 | Bergstrom Donald A | President, R&D | Sell | 27K | $3.68 | $98K | 553K |
| 2025-07-29 | Adams Brian | Chief Legal Officer | Sell | 18K | $3.68 | $67K | 371K |
| 2025-07-28 | Rahmer Peter | See remarks | Sell | 1K | $3.74 | $5K | 394K |
| 2025-07-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $3.74 | $6K | 354K |
| 2025-07-28 | Bergstrom Donald A | President, R&D | Sell | 4K | $3.74 | $15K | 579K |
| 2025-07-28 | Adams Brian | Chief Legal Officer | Sell | 2K | $3.74 | $6K | 390K |
| 2025-07-09 | Patel Sanjiv | President and CEO | Sell | 19K | $3.57 | $67K | 765K |
| 2025-07-09 | Patel Sanjiv | President and CEO | Sell | 43K | $3.57 | $153K | 784K |
| 2025-06-30 | Rahmer Peter | See remarks | Grant | 5K | $2.94 | $15K | 395K |
| 2025-06-30 | Patel Sanjiv | President and CEO | Grant | 5K | $2.94 | $15K | 827K |
| 2025-04-30 | Adams Brian | Chief Legal Officer | Sell | 13K | $3.00 | $39K | 391K |
| 2025-04-30 | Bergstrom Donald A | President, R&D | Sell | 27K | $3.00 | $82K | 583K |
| 2025-04-30 | Catinazzo Thomas | Chief Financial Officer | Sell | 13K | $3.00 | $39K | 355K |
| 2025-04-30 | Rahmer Peter | See remarks | Sell | 11K | $3.00 | $32K | 390K |
| 2025-04-29 | Catinazzo Thomas | Chief Financial Officer | Sell | 4K | $3.23 | $11K | 368K |
| 2025-04-28 | Adams Brian | Chief Legal Officer | Sell | 2K | $3.17 | $5K | 404K |
| 2025-04-28 | Bergstrom Donald A | President, R&D | Sell | 4K | $3.17 | $13K | 611K |
| 2025-04-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $3.17 | $5K | 373K |
| 2025-04-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 981 | $3.17 | $3K | 372K |
| 2025-04-28 | Rahmer Peter | See remarks | Sell | 1K | $3.17 | $4K | 401K |
| 2025-04-23 | Patel Sanjiv | President and CEO | Sell | 43K | $2.97 | $127K | 840K |
| 2025-04-23 | Patel Sanjiv | President and CEO | Sell | 19K | $2.97 | $55K | 822K |
| 2025-03-27 | Adams Brian | Chief Legal Officer | Sell | 298 | $2.84 | $846 | 406K |
| 2025-03-27 | Catinazzo Thomas | Chief Financial Officer | Sell | 298 | $2.84 | $846 | 379K |
| 2025-03-27 | Catinazzo Thomas | Chief Financial Officer | Sell | 5K | $2.84 | $13K | 375K |
| 2025-03-27 | Rahmer Peter | See remarks | Sell | 247 | $2.84 | $701 | 402K |
| 2025-03-27 | Bergstrom Donald A | President, R&D | Sell | 986 | $2.84 | $3K | 615K |
| 2025-02-13 | Patel Sanjiv | President and CEO | Sell | 75K | $3.70 | $279K | 883K |
| 2025-02-11 | Patel Sanjiv | President and CEO | Sell | 140K | $3.85 | $540K | 626K |
| 2025-02-11 | Patel Sanjiv | President and CEO | Grant | 332K | $0.00 | $0 | 958K |
| 2025-01-30 | Adams Brian | Chief Legal Officer | Sell | 21K | $4.42 | $92K | 406K |
| 2025-01-30 | Bergstrom Donald A | President, R&D | Sell | 31K | $4.42 | $136K | 616K |
| 2025-01-30 | Catinazzo Thomas | Chief Financial Officer | Sell | 21K | $4.42 | $92K | 379K |
| 2025-01-30 | Rahmer Peter | See remarks | Sell | 17K | $4.42 | $76K | 402K |
| 2025-01-29 | Bergstrom Donald A | President, R&D | Sell | 46K | $4.55 | $211K | 647K |
| 2025-01-29 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $4.55 | $10K | 400K |
| 2025-01-29 | Rahmer Peter | See remarks | Sell | 27K | $4.55 | $121K | 420K |
| 2025-01-28 | Adams Brian | Chief Legal Officer | Grant | 139K | $0.00 | $0 | 427K |
| 2025-01-28 | Adams Brian | Chief Legal Officer | Sell | 34K | $4.63 | $156K | 288K |
| 2025-01-28 | Bergstrom Donald A | President, R&D | Sell | 3K | $4.63 | $15K | 517K |
| 2025-01-28 | Bergstrom Donald A | President, R&D | Grant | 176K | $0.00 | $0 | 693K |
| 2025-01-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 2K | $4.63 | $11K | 263K |
| 2025-01-28 | Catinazzo Thomas | Chief Financial Officer | Grant | 139K | $0.00 | $0 | 402K |
| 2025-01-28 | Catinazzo Thomas | Chief Financial Officer | Sell | 34K | $4.63 | $156K | 265K |
| 2025-01-28 | Rahmer Peter | See remarks | Grant | 139K | $0.00 | $0 | 446K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON15 Form 144 notices on file for RLAY worth $141.2M at the prices reported; 4 in the last 90 days worth $128.1M. Latest: SANJIV PATEL filed on 2026-10-07 to sell 96,401 shares ($1.8M) from 2026-10-07.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-07 | SANJIV PATELDirector, Officer | 96K | $1.8M | 0.044% | 2026-10-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-06 | THOMAS CATINAZZOOfficer | 93K | $1.8M | 0.043% | 2026-10-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-26 | PETER RAHMEROfficer | 50K | $1.0M | 0.023% | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | SVF Pauling (Cayman) LtdStockholder | 6.0M | $123.4M | 2.738% | 2026-08-25 | Citigroup Global Markets Inc. |
| 2026-08-04 | SEKAR KATHIRESANDirector | 42K | $826K | 0.022% | 2026-08-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-31 | SEKAR KATHIRESANDirector | 30K | $564K | 0.016% | 2026-07-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-21 | SEKAR KATHIRESANDirector | 30K | $594K | 0.016% | 2026-07-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-20 | SEKAR KATHIRESANDirector | 66K | $1.3M | 0.034% | 2026-07-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | SANJIV PATELDirector, Officer | 145K | $2.7M | 0.075% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | PETER RAHMEROfficer | 50K | $987K | 0.026% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | THOMAS CATINAZZOOfficer | 205K | $3.3M | 0.107% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-22 | DONALD BERGSTROMOfficer | 111K | $1.8M | 0.058% | 2026-06-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-14 | THOMAS CATINAZZOOfficer | 37K | $492K | 0.019% | 2026-05-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-09 | THOMAS CATINAZZOOfficer | 53K | $526K | 0.030% | 2026-03-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-29 | Peter J RahmerOfficer | 21K | $160K | 0.012% | 2025-10-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of RLAY in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 10.0% of the class (21,270,751 shares), filed 2026-08-07 for an event on 2026-07-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 3 | Commodore Capital Master LPpartnership | 12.0M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Robert Egen Atkinsonparent holding company, individual | 12.0M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Commodore Capital LPinvestment adviser, partnership | 12.0M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Michael Kramarzparent holding company, individual | 12.0M | 5.5% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 14.1M | 6.4% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Joseph Edelmanindividual | 14.1M | 6.4% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 14.1M | 6.4% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 1 | FMR LLCparent holding company | 21.3M | 10.0% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 21.3M | 10.0% | 2026-07-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Asset Management, L.P.partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Capital Advisors, Inc.corporation | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Steven A. Cohenindividual | 0 | 0.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 2 | CASDIN CAPITAL, LLCinvestment adviser | 13.0M | 7.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | CASDIN PARTNERS GP, LLCother entity | 13.0M | 7.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | ELI CASDINparent holding company, individual | 13.0M | 7.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 2 | CASDIN PARTNERS MASTER FUND, L.P.partnership | 12.6M | 7.3% | 2025-12-31 |
13F holders
Tracked managers holding RLAY at their latest 13F. JSON6 of the 30 tracked managers held RLAY at their latest 13F, $67.1M in total at quarter-end prices. AQR Capital Management is the largest at $23.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 1.3M | $23.9M | 0.01% | -11K |
| Two Sigma Investments | 2026-06-30 | 701K | $13.1M | 0.01% | -668K |
| Millennium Management | 2026-06-30 | 592K | $11.1M | 0.00% | +244K |
| Citadel Advisors | 2026-06-30 | 474K | $8.9M | 0.00% | +297K |
| Duquesne Family Office | 2026-06-30 | 349K | $6.5M | 0.13% | new |
| Renaissance Technologies | 2026-06-30 | 192K | $3.6M | 0.01% | -481K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Relay Therapeutics reported revenue of $350K, down 48.3% from the same quarter a year earlier, and net loss of $83.7M (-0.41 diluted EPS). In FY 2025 it generated -$235.5M of operating cash flow.
- Cash
- $121.2M
- Equity
- $890.0M
- Total assets
- $967.5M
- Shares outstanding
- 219,141,631
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $350K | -$83.7M | -23916.3% | -0.41 |
| Q1 FY 2026 | 2026-03-31 | $3.0M | -$73.3M | -2443.0% | -0.41 |
| Q4 FY 2025derived | 2025-12-31 | $7.0M | -$54.9M | -784.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $0 | -$74.1M | n/a | -0.43 |
| Q2 FY 2025 | 2025-06-30 | $677K | -$70.4M | -10395.1% | -0.41 |
| Q1 FY 2025 | 2025-03-31 | $7.7M | -$77.1M | -1003.6% | -0.46 |
| Q4 FY 2024derived | 2024-12-31 | $0 | -$76.0M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $0 | -$88.1M | n/a | -0.63 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $15.4M | -$276.5M | -$235.5M | $410K | n/a | n/a |
| FY 2024 | 2024-12-31 | $10.0M | -$337.7M | -$249.1M | $2.0M | n/a | n/a |
| FY 2023 | 2023-12-31 | $25.5M | -$342.0M | -$300.3M | $4.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.4M | -$290.5M | -$229.5M | $9.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $3.0M | -$363.9M | -$74.4M | $3.5M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Relay Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Relay Therapeutics (RLAY), SEC CIK 1812364, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-07.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 1812364Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of RLAY is sold short?
44,026,826 shares were held short at the 2026-10-15 settlement, 16.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RLAY's daily short volume?
On 2026-11-02, 1,288,284 of the 1,623,508 RLAY shares reported to FINRA were sold short, 79.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RLAY have fails to deliver?
The SEC's latest file shows 440,875 RLAY shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are RLAY insiders buying or selling?
Insiders at RLAY reported 13 open-market sells worth $120.5M in the last 90 days and no open-market buys. Latest filing: Catinazzo Thomas (Chief Financial Officer) on 2026-10-28.
Have RLAY insiders filed to sell?
15 Form 144 notices on file for RLAY worth $141.2M at the prices reported; 4 in the last 90 days worth $128.1M. Latest: SANJIV PATEL filed on 2026-10-07 to sell 96,401 shares ($1.8M) from 2026-10-07.
Who owns 5% or more of RLAY?
13 holders report 5% or more of RLAY in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 10.0% of the class (21,270,751 shares), filed 2026-08-07 for an event on 2026-07-31.
What did RLAY report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Relay Therapeutics reported revenue of $350K, down 48.3% from the same quarter a year earlier, and net loss of $83.7M (-0.41 diluted EPS). In FY 2025 it generated -$235.5M of operating cash flow.
Which tracked 13F managers own RLAY?
6 of the 30 tracked 13F managers held RLAY shares at their latest filing, $67.1M in all. The largest: Cliff Asness's AQR Capital Management (1.3M shares, $23.9M), Two Sigma Investments (701K shares, $13.1M), Izzy Englander's Millennium Management (592K shares, $11.1M), Ken Griffin's Citadel Advisors (474K shares, $8.9M), Stanley Druckenmiller's Duquesne Family Office (349K shares, $6.5M), Renaissance Technologies (192K shares, $3.6M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.